Diversified Trust Co Has $721,000 Stock Position in LivaNova PLC (NASDAQ:LIVN)

Diversified Trust Co raised its position in LivaNova PLC (NASDAQ:LIVN) by 6.6% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 12,890 shares of the company’s stock after acquiring an additional 796 shares during the period. Diversified Trust Co’s holdings in LivaNova were worth $721,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of LIVN. Headlands Technologies LLC grew its position in LivaNova by 33.3% in the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after purchasing an additional 451 shares during the period. Teza Capital Management LLC bought a new stake in LivaNova during the third quarter worth $275,000. Vanguard Personalized Indexing Management LLC raised its position in LivaNova by 34.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock valued at $286,000 after buying an additional 1,418 shares during the last quarter. Aigen Investment Management LP bought a new position in LivaNova during the 4th quarter valued at $286,000. Finally, Pacer Advisors Inc. boosted its holdings in LivaNova by 80.8% during the 4th quarter. Pacer Advisors Inc. now owns 8,102 shares of the company’s stock worth $419,000 after acquiring an additional 3,621 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LIVN. Mizuho raised their price target on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Robert W. Baird lifted their price target on LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 target price on shares of LivaNova in a research report on Thursday, June 6th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $66.20.

Insider Buying and Selling at LivaNova

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the transaction, the director now owns 27,534 shares in the company, valued at $1,655,068.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.27% of the company’s stock.

LivaNova Trading Down 2.9 %

NASDAQ:LIVN opened at $52.89 on Wednesday. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47. The company has a current ratio of 3.17, a quick ratio of 2.71 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $57.89 and its 200 day moving average is $54.25. The stock has a market capitalization of $2.86 billion, a PE ratio of -88.15 and a beta of 0.99.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.28. The firm had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The business’s revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 earnings per share. Sell-side analysts expect that LivaNova PLC will post 2.6 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.